Haigang Chen, Ph.D.
VP, CMC

Dr. Chen has 18 years of experience in biopharmaceutical industry, he brings expertise across various therapeutic modalities. Dr. Chen has been involved in the development of over 15 compounds and has successfully managed the submission of several NDA/ANDAs.

Prior to joining Terns, Dr. Chen held progressively responsible positions in CMC at several companies, including Principia Biopharma (acquired by Sanofi), Bausch Health, Perrigo, and Corcept. During his tenure at Principia, he oversaw phase 3 product development, focusing on registration, validation, and NDA submission.

Dr. Chen earned his bachelor’s degree in Chemistry from Tsinghua University in Beijing and completed his Ph.D. in Pharmaceutical and Chemical Sciences at the University of the Pacific in Stockton.